certolizumab pegol vs golimumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Crohn's DiseasePEGylated anti-TNF Fab' fragment
Weak signal

NCT00552344 · Phase 3 · completed

This open-label study gave long-term certolizumab pegol to patients with Crohn's disease from study C87085. Its primary objective was safety and its primary outcomes were adverse events, so there is no efficacy result to call met or missed. Over up to 272 weeks, 89.6% of patients had an adverse event and 37.1% a serious one. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Percentage of Subjects in Clinical Remission at Week 6: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported (missed)

Result source: NCT00552058

golimumab · Simponi

Marketed by Johnson & Johnson

Phase 2 in Crohn's Diseasemonoclonal antibody (fully human IgG1)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcertolizumab pegolgolimumab
Clinical remission (induction)31.6% vs 25.4%+6.2 vs placebowk 6 · n 215NCT00552058
2 other results
  • 26.5% vs 19.1% wk 4 · n 215 · Phase 3 · secondary NCT00552058
  • 23.3% vs 15.8% wk 2 · n 215 · Phase 3 · secondary NCT00552058
—Not reported
Endoscopic response (induction)—Not posted · NCT00152425—Not reported
Clinical remission (maintenance)37.5% vs 35%+2.5 vs placebowk 34 · n 16NCT00356408
1 other result
  • 3% vs 35% wk 34 · n 33 · Phase 3 · secondary NCT00356408
—Not reported
Endoscopic response (maintenance)—Not posted · NCT00152425—Not reported

Clinical remission (induction)

certolizumab pegol
31.6% vs 25.4%+6.2 vs placebowk 6 · n 215NCT00552058
2 other results
  • 26.5% vs 19.1% wk 4 · n 215 · Phase 3 · secondary NCT00552058
  • 23.3% vs 15.8% wk 2 · n 215 · Phase 3 · secondary NCT00552058
golimumab
—Not reported

Endoscopic response (induction)

certolizumab pegol
—Not posted · NCT00152425
golimumab
—Not reported

Clinical remission (maintenance)

certolizumab pegol
37.5% vs 35%+2.5 vs placebowk 34 · n 16NCT00356408
1 other result
  • 3% vs 35% wk 34 · n 33 · Phase 3 · secondary NCT00356408
golimumab
—Not reported

Endoscopic response (maintenance)

certolizumab pegol
—Not posted · NCT00152425
golimumab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

golimumab: registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. certolizumab pegol: 4 of 4 rows · golimumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccertolizumab pegol
Dropout rate
78.4%a
NCT00552344 · Phase 3 · monotherapy
show 24 more results
80.3%
NCT00160524 · Phase 3 · monotherapy
—400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
—400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
69.5%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
92.3%
NCT00160706 · Phase 3 · monotherapy
—400 mg
NCT00356408 · Phase 3 · monotherapy
—CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
—CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
7.2%
NCT00552058 · Phase 3 · monotherapy
40.4%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
46.2%400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
53.3%400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
25%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
3.1%400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00552344 · Phase 3 · monotherapy
show 24 more results
35.8%
NCT00160524 · Phase 3 · monotherapy
—400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
—400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
18.9%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
51%
NCT00160706 · Phase 3 · monotherapy
—400 mg
NCT00356408 · Phase 3 · monotherapy
—CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
—CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
3.6%
NCT00552058 · Phase 3 · monotherapy
14.6%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
—400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
—400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
12.5%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Serious AEs
37.1%a
NCT00552344 · Phase 3 · monotherapy
show 24 more results
40.3%
NCT00160524 · Phase 3 · monotherapy
13.4%400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
13.4%400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
31.9%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
44.5%
NCT00160706 · Phase 3 · monotherapy
14.6%400 mg
NCT00356408 · Phase 3 · monotherapy
0%CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
12.1%CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
5.4%
NCT00552058 · Phase 3 · monotherapy
38.2%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
0%Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
40%High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
0%Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
50%Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
23.1%400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
33.3%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
31.3%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
9.4%400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
crohn's disease 31.6%
abdominal pain 18.7%
upper respiratory tract infection 15.7%
NCT00552344 · Phase 3 · monotherapy
show 21 more results
crohn's disease 21.8%
nasopharyngitis 15.3%
abdominal pain 15%
NCT00160524 · Phase 3 · monotherapy
400 mg every 2 weeks
nasopharyngitis 17.2%
pyrexia 11.8%
arthralgia 10.8%
NCT00308581 · Phase 3 · monotherapy
400 mg every 4 weeks
headache 16.6%
nasopharyngitis 12.3%
nausea 11.2%
NCT00308581 · Phase 3 · monotherapy
400 mg
nasopharyngitis 27.5%
headache 20.5%
pyrexia 20.5%
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 34.5%
abdominal pain 20%
arthralgia 15.8%
NCT00160706 · Phase 3 · monotherapy
400 mg
crohn's disease 21.4% (placebo 7.1%)
arthralgia 18.4% (placebo 0%)
upper respiratory tract infection 13.6% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
arthralgia 25% (placebo 0%)
myalgia 18.8% (placebo 0%)
sinusitis 18.8% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
crohn's disease 33.3% (placebo 7.1%)
arthralgia 21.2% (placebo 0%)
nausea 18.2% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
headache 5.4% (placebo 4.7%)
abdominal pain 4.5% (placebo 3.7%)
arthralgia 4% (placebo 2.8%)
NCT00552058 · Phase 3 · monotherapy
400 mg
headache 33.7%
arthralgia 30.3%
nasopharyngitis 23.6%
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
High-dose (Weight Adjusted)
abdominal pain upper 40%
nasopharyngitis 20%
nausea 20%
NCT01190410 · Phase 2 · registry result, not featured evidence
Low-dose (Weight Adjusted)
asthma exercise induced 25%
cough 25%
dizziness 25%
NCT01190410 · Phase 2 · registry result, not featured evidence
Re-Induction
abdominal injury 50%
anal fissure 50%
c-reactive protein increased 50%
NCT01190410 · Phase 2 · registry result, not featured evidence
400 mg / 200 mg
pyrexia 46.2% (placebo 11.1%)
nasopharyngitis 38.5% (placebo 55.6%)
contusion 15.4% (placebo 0%)
NCT00329420 · Phase 2 · registry result, not featured evidence
400 mg / 400 mg
nasopharyngitis 40% (placebo 55.6%)
pyrexia 20% (placebo 11.1%)
nausea 13.3% (placebo 5.6%)
NCT00329420 · Phase 2 · registry result, not featured evidence
nasopharyngitis 20% (placebo 22.2%)
nausea 13.3% (placebo 22.2%)
urinary tract infection 13.3% (placebo 0%)
NCT00329550 · Phase 2 · registry result, not featured evidence
nasopharyngitis 62.5% (placebo 22.2%)
dna antibody positive 12.5% (placebo 22.2%)
headache 12.5% (placebo 0%)
NCT00329550 · Phase 2 · registry result, not featured evidence
400 mg
nasopharyngitis 21.9% (placebo 31.3%)
nausea 6.3% (placebo 3.1%)
pharynx discomfort 6.3% (placebo 0%)
NCT00291668 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 23.3% (placebo 31.3%)
nausea 6.7% (placebo 3.1%)
pharyngolaryngeal pain 6.7% (placebo 0%)
NCT00291668 · Phase 2 · registry result, not featured evidence
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 21 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

certolizumab pegol

Clinical Remission 46.1% (n=89) @ 10wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 2 more results
27% (n=89) @ 54wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
54.7% (n=592) @ 364wk
NCT00160524 · Phase 3 · monotherapy
HBI 21.7% (n=594) @ 364wk
responder rate · % of participants
No placebo or comparator arm
NCT00160524 · Phase 3 · monotherapy
show 2 more results
52.8% (n=307) @ 362wk
NCT00160706 · Phase 3 · monotherapy
65.6% (n=299) @ 362wk
NCT00160706 · Phase 3 · monotherapy
CDAI-100 37.4% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 70 participants as posted
show 1 more result
35.5% (n=186) @ 26wk*400 mg every 2 weeks
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 66 participants as posted
CDAI-70 40.1% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 75 participants as posted
show 1 more result
40.3% (n=186) @ 26wk*400 mg every 2 weeks
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 75 participants as posted
Clinical Remission 27.3% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Remission
NCT00308581 · Phase 3 · monotherapy · converted to % from 51 participants as posted
show 1 more result
28% (n=186) @ 26wk*400 mg every 2 weeks
Remission
NCT00308581 · Phase 3 · monotherapy · converted to % from 52 participants as posted
CDAI 175.62 score @ 8wk400 mg every 4 weeks
absolute value · score
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy
show 19 more results
169.18 score @ 8wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
164.65 score @ 10wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
162.86 score @ 10wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
173.83 score @ 12wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
163.78 score @ 12wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
162.34 score @ 14wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
158.68 score @ 14wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
163.73 score @ 16wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
156.05 score @ 16wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
153.38 score @ 18wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
156.64 score @ 18wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
162.79 score @ 20wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
138.6 score @ 20wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
128.13 score @ 22wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
141.89 score @ 22wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
135.49 score @ 24wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
139.5 score @ 24wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
122.37 score @ 26wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
131.41 score @ 26wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
CDAI -133.35 score @ 8wk400 mg every 4 weeks
absolute change · score
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy
show 19 more results
-137.7 score @ 8wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-145.16 score @ 10wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-145.26 score @ 10wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-134.51 score @ 12wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-145.17 score @ 12wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-145.54 score @ 14wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.08 score @ 14wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-141.9 score @ 16wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.89 score @ 16wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-150.38 score @ 18wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.66 score @ 18wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-139.98 score @ 20wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-162.85 score @ 20wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-171.52 score @ 22wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-159.13 score @ 22wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-165.06 score @ 24wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-160.44 score @ 24wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-176.85 score @ 26wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-168.59 score @ 26wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
Duration of Response 4.21 months400 mg every 4 weeks
time to event · months
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to months from 128 days as posted
show 1 more result
4.11 months*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to months from 125 days as posted
Steroid-free Remission 2.6% (n=76) @ 10wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
show 17 more results
2.6% (n=78) @ 10wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
3.9% (n=76) @ 12wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
5.1% (n=78) @ 12wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
3.9% (n=76) @ 14wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
3.8% (n=78) @ 14wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
6.6% (n=76) @ 16wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.3% (n=78) @ 16wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
9.2% (n=76) @ 18wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
9% (n=78) @ 18wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
10.5% (n=76) @ 20wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
7.7% (n=78) @ 20wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 6 participants as posted
10.5% (n=76) @ 22wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
9% (n=78) @ 22wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
11.8% (n=76) @ 24wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
6.4% (n=78) @ 24wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.5% (n=76) @ 26wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
6.4% (n=78) @ 26wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
Steroid Free 2.6% (n=76) @ 10wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
show 17 more results
2.6% (n=78) @ 10wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
5.3% (n=76) @ 12wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
5.1% (n=78) @ 12wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
6.6% (n=76) @ 14wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
6.4% (n=78) @ 14wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.5% (n=76) @ 16wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
12.8% (n=78) @ 16wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 10 participants as posted
11.8% (n=76) @ 18wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
10.3% (n=78) @ 18wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
11.8% (n=76) @ 20wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
9% (n=78) @ 20wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
11.8% (n=76) @ 22wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
10.3% (n=78) @ 22wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
14.5% (n=76) @ 24wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 11 participants as posted
6.4% (n=78) @ 24wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
13.2% (n=76) @ 26wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 10 participants as posted
7.7% (n=78) @ 26wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 6 participants as posted
Maintenance of 61.8% (n=166)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
CDAI 53.3% (n=229)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 2 more results
50.6% (n=89) @ 10wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
32.6% (n=89) @ 54wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3

+ 28 further endpoints in the CSV export.

Psoriatic Arthritis

Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Psoriatic ArthritisPEGylated anti-TNF Fab' fragment
Weak signal

NCT03357471 · Phase 3 · completed

Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.

No aligned efficacy figure on record for this race.

golimumab · Simponi

Marketed by Johnson & Johnson

Approved in Psoriatic Arthritismonoclonal antibody (fully human IgG1)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Reported efficacy

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% (met)

Result source: NCT02181673

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcertolizumab pegolgolimumab
ACR2051.9% vs 24.3%+27.6 vs placebo400 mg Q4W · wk 12 · n 135NCT01087788
3 other results
  • 58% vs 24.3% 200 mg Q2W · wk 12 · n 138 · Phase 3 · primary NCT01087788
  • 56.3% vs 23.5% 400 mg Q4W · wk 24 · n 135 · Phase 3 · secondary NCT01087788
  • 63.8% vs 23.5% 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788
45.2% vs 8.8%+36.4 vs placebo100 mg · wk 14 · n 146NCT00265096
6 other results
  • 50.7% vs 8.8% 50 mg · wk 14 · n 146 · Phase 3 · primary NCT00265096
  • 75.1% vs 21.8% wk 14 · n 241 · Phase 3 · primary NCT02181673
  • 65.1% vs 65.9% wk 24 · n 43 · Phase 3 · secondary NCT04108468
  • 65.1% vs 56.1% wk 12 · n 43 · Phase 3 · secondary NCT04108468
  • 62.8% vs 58.5% wk 36 · n 43 · Phase 3 · secondary NCT04108468
  • 53.5% vs 68.3% wk 52 · n 43 · Phase 3 · secondary NCT04108468
ACR50—Not reported53.5% vs 6.3%+47.2 vs placebowk 24 · n 241NCT02181673
5 other results
  • 43.6% vs 6.3% wk 14 · n 241 · Phase 3 · secondary NCT02181673
  • 37.2% vs 36.6% wk 52 · n 43 · Phase 3 · secondary NCT04108468
  • 48.8% vs 39% wk 36 · n 43 · Phase 3 · secondary NCT04108468
  • 48.8% vs 36.6% wk 24 · n 43 · Phase 3 · secondary NCT04108468
  • 46.5% vs 29.3% wk 12 · n 43 · Phase 3 · secondary NCT04108468
PASI 7560.5% vs 15.1%+45.4 vs placebo400 mg Q4W · wk 24 · n 76NCT01087788
1 other result
  • 62.2% vs 15.1% 200 mg Q2W · wk 24 · n 90 · Phase 3 · secondary NCT01087788
58.3% vs 2.5%+55.8 vs placebo100 mg · wk 14 · n 108NCT00265096
6 other results
  • 40.4% vs 2.5% 50 mg · wk 14 · n 109 · Phase 3 · secondary NCT00265096
  • 59.2% vs 13.6% wk 14 · n 196 · Phase 3 · secondary NCT02181673
  • 84.6% vs 37.5% wk 24 · n 13 · Phase 3 · secondary NCT04108468
  • 53.8% vs 0% wk 12 · n 13 · Phase 3 · secondary NCT04108468
  • 69.2% vs 25% wk 36 · n 13 · Phase 3 · secondary NCT04108468
  • 46.2% vs 25% wk 52 · n 13 · Phase 3 · secondary NCT04108468
Minimal disease activity—Not reported39.5% vs 48.8%vs Methotrexatewk 52 · n 43NCT04108468
3 other results
  • 58.1% vs 53.7% wk 36 · n 43 · Phase 3 · secondary NCT04108468
  • 55.8% vs 58.5% wk 24 · n 43 · Phase 3 · secondary NCT04108468
  • 46.5% vs 43.9% wk 12 · n 43 · Phase 3 · secondary NCT04108468
HAQ-DI, change-0.5 vs -0.2−0.3 vs placebo400 mg Q4W · wk 24 · n 135NCT01087788
1 other result
  • -0.5 vs -0.2 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788
0.4 vs 0+0.4 vs placebo100 mg · wk 24 · n 146NCT00265096
2 other results
  • 0.3 vs 0 50 mg · wk 24 · n 146 · Phase 3 · secondary NCT00265096
  • -0.6 vs -0.1 wk 14 · n 233 · Phase 3 · secondary NCT02181673

ACR20

certolizumab pegol
51.9% vs 24.3%+27.6 vs placebo400 mg Q4W · wk 12 · n 135NCT01087788
3 other results
  • 58% vs 24.3% 200 mg Q2W · wk 12 · n 138 · Phase 3 · primary NCT01087788
  • 56.3% vs 23.5% 400 mg Q4W · wk 24 · n 135 · Phase 3 · secondary NCT01087788
  • 63.8% vs 23.5% 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788
golimumab
45.2% vs 8.8%+36.4 vs placebo100 mg · wk 14 · n 146NCT00265096
6 other results
  • 50.7% vs 8.8% 50 mg · wk 14 · n 146 · Phase 3 · primary NCT00265096
  • 75.1% vs 21.8% wk 14 · n 241 · Phase 3 · primary NCT02181673
  • 65.1% vs 65.9% wk 24 · n 43 · Phase 3 · secondary NCT04108468
  • 65.1% vs 56.1% wk 12 · n 43 · Phase 3 · secondary NCT04108468
  • 62.8% vs 58.5% wk 36 · n 43 · Phase 3 · secondary NCT04108468
  • 53.5% vs 68.3% wk 52 · n 43 · Phase 3 · secondary NCT04108468

ACR50

certolizumab pegol
—Not reported
golimumab
53.5% vs 6.3%+47.2 vs placebowk 24 · n 241NCT02181673
5 other results
  • 43.6% vs 6.3% wk 14 · n 241 · Phase 3 · secondary NCT02181673
  • 37.2% vs 36.6% wk 52 · n 43 · Phase 3 · secondary NCT04108468
  • 48.8% vs 39% wk 36 · n 43 · Phase 3 · secondary NCT04108468
  • 48.8% vs 36.6% wk 24 · n 43 · Phase 3 · secondary NCT04108468
  • 46.5% vs 29.3% wk 12 · n 43 · Phase 3 · secondary NCT04108468

PASI 75

certolizumab pegol
60.5% vs 15.1%+45.4 vs placebo400 mg Q4W · wk 24 · n 76NCT01087788
1 other result
  • 62.2% vs 15.1% 200 mg Q2W · wk 24 · n 90 · Phase 3 · secondary NCT01087788
golimumab
58.3% vs 2.5%+55.8 vs placebo100 mg · wk 14 · n 108NCT00265096
6 other results
  • 40.4% vs 2.5% 50 mg · wk 14 · n 109 · Phase 3 · secondary NCT00265096
  • 59.2% vs 13.6% wk 14 · n 196 · Phase 3 · secondary NCT02181673
  • 84.6% vs 37.5% wk 24 · n 13 · Phase 3 · secondary NCT04108468
  • 53.8% vs 0% wk 12 · n 13 · Phase 3 · secondary NCT04108468
  • 69.2% vs 25% wk 36 · n 13 · Phase 3 · secondary NCT04108468
  • 46.2% vs 25% wk 52 · n 13 · Phase 3 · secondary NCT04108468

Minimal disease activity

certolizumab pegol
—Not reported
golimumab
39.5% vs 48.8%vs Methotrexatewk 52 · n 43NCT04108468
3 other results
  • 58.1% vs 53.7% wk 36 · n 43 · Phase 3 · secondary NCT04108468
  • 55.8% vs 58.5% wk 24 · n 43 · Phase 3 · secondary NCT04108468
  • 46.5% vs 43.9% wk 12 · n 43 · Phase 3 · secondary NCT04108468

HAQ-DI, change

certolizumab pegol
-0.5 vs -0.2−0.3 vs placebo400 mg Q4W · wk 24 · n 135NCT01087788
1 other result
  • -0.5 vs -0.2 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788
golimumab
0.4 vs 0+0.4 vs placebo100 mg · wk 24 · n 146NCT00265096
2 other results
  • 0.3 vs 0 50 mg · wk 24 · n 146 · Phase 3 · secondary NCT00265096
  • -0.6 vs -0.1 wk 14 · n 233 · Phase 3 · secondary NCT02181673
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. certolizumab pegol: 4 of 4 rows · golimumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccertolizumab pegolgolimumab
Rows use multiple source trials
Dropout rate
—400 mg Q4Wa
NCT01087788 · Phase 3
show 6 more results
—200 mg Q2W
NCT01087788 · Phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
6%b
NCT03733925 · Phase 4 · registry result, not featured evidence
show 7 more results
9.3%
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
4.8%
NCT02065713 · Phase 3 · registry result, not featured evidence · combination
4.6%2 mg/kg
NCT02181673 · Phase 3 · registry result, not featured evidence
—100 mg
NCT00265096 · Phase 3 · registry result, not featured evidence
—50 and 100 mg
NCT00265096 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00265096 · Phase 3 · registry result, not featured evidence
18.6%100 mg q4w + 50 mg q4w
NCT05071664 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—400 mg Q4Wa
NCT01087788 · Phase 3
show 6 more results
—200 mg Q2W
NCT01087788 · Phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
2%b
NCT03733925 · Phase 4 · registry result, not featured evidence
show 7 more results
—
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
4.8%
NCT02065713 · Phase 3 · registry result, not featured evidence · combination
1.2%2 mg/kg
NCT02181673 · Phase 3 · registry result, not featured evidence
—100 mg
NCT00265096 · Phase 3 · registry result, not featured evidence
—50 and 100 mg
NCT00265096 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00265096 · Phase 3 · registry result, not featured evidence
—100 mg q4w + 50 mg q4w
NCT05071664 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
26.2%400 mg Q4Wa
NCT01087788 · Phase 3
show 6 more results
24.7%200 mg Q2W
NCT01087788 · Phase 3
0%Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
4%b
NCT03733925 · Phase 4 · registry result, not featured evidence
show 7 more results
0%
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02065713 · Phase 3 · registry result, not featured evidence · combination
7.9%2 mg/kg
NCT02181673 · Phase 3 · registry result, not featured evidence
22.9%100 mg
NCT00265096 · Phase 3 · registry result, not featured evidence
19.9%50 and 100 mg
NCT00265096 · Phase 3 · registry result, not featured evidence
20.9%50 mg
NCT00265096 · Phase 3 · registry result, not featured evidence
6.8%100 mg q4w + 50 mg q4w
NCT05071664 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
400 mg Q4Wa
upper respiratory tract infection 25.1%
nasopharyngitis 21.5%
pharyngitis 13.8%
NCT01087788 · Phase 3
show 3 more results
200 mg Q2W
nasopharyngitis 22.7%
upper respiratory tract infection 22.2%
hypertension 15.2%
NCT01087788 · Phase 3
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence
b
nasopharyngitis 5%
cough 4%
pyrexia 4%
NCT03733925 · Phase 4 · registry result, not featured evidence
show 7 more results
alanine aminotransferase increased 48.8%
upper respiratory infection 41.9%
nausea 37.2%
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
arthralgia 14.3% (placebo 4.3%)
folliculitis 14.3% (placebo 0%)
transaminases increased 14.3% (placebo 17.4%)
NCT02065713 · Phase 3 · registry result, not featured evidence · combination
2 mg/kg
alanine aminotransferase increased 10.4% (placebo 2.1%)
aspartate aminotransferase increased 7.9% (placebo 2.1%)
nasopharyngitis 5.8% (placebo 5.4%)
NCT02181673 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 31.2%
nasopharyngitis 25.7%
back pain 16.5%
NCT00265096 · Phase 3 · registry result, not featured evidence
50 and 100 mg
upper respiratory tract infection 28.1%
nasopharyngitis 21.2%
hypertension 16.4%
NCT00265096 · Phase 3 · registry result, not featured evidence
50 mg
upper respiratory tract infection 31.7%
nasopharyngitis 16.5%
headache 15.1%
NCT00265096 · Phase 3 · registry result, not featured evidence
100 mg q4w + 50 mg q4w
diarrhoea 11.9%
headache 11.9%
covid-19 8.5%
NCT05071664 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 5 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

certolizumab pegol

Modified Sharp 25.05 vs 28.92 placebo score @ 24wk400 mg Q4W
absolute change · score
Pre-defined results
NCT01087788 · Phase 3
show 1 more result
11.52 vs 28.92 placebo score @ 24wk200 mg Q2W
Pre-defined results
NCT01087788 · Phase 3
Modified Sharp 0.11 vs 0.32 placebo score @ 48wk400 mg Q4W
absolute change · score
Predefined results: Overall
NCT01087788 · Phase 3
show 1 more result
0.15 vs 0.32 placebo score @ 48wk200 mg Q2W
Predefined results: Overall
NCT01087788 · Phase 3

golimumab

ASAS20 74.5% (n=47) @ 14wk
responder rate · % of participants
No placebo or comparator arm
NCT03733925 · Phase 4 · registry result, not featured evidence
show 1 more result
66% (n=47) @ 24wk
NCT03733925 · Phase 4 · registry result, not featured evidence
ACR20 84.6% (n=39) @ 14wk
responder rate · % of participants
No placebo or comparator arm
NCT03733925 · Phase 4 · registry result, not featured evidence
show 1 more result
93.2% (n=44) @ 24wk
NCT03733925 · Phase 4 · registry result, not featured evidence
PASDAS 2.7 vs 3.09 Methotrexate score @ 24wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
3.01 vs 3.7 Methotrexate score @ 12wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
2.93 vs 3.3 Methotrexate score @ 36wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
3.42 vs 3.36 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
CPDAI 3.49 vs 4.1 Methotrexate score @ 12wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
3.12 vs 3.24 Methotrexate score @ 24wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
3.17 vs 2.97 Methotrexate score @ 36wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
3.49 vs 3.03 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
Patient Global VAS 27.72 vs 27.56 Methotrexate score @ 24wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
36.57 vs 32.73 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
SF-36 PCS 46.1 vs 45.62 Methotrexate score @ 24wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
42.8 vs 44.44 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
SF-36 MCS 51.27 vs 52.11 Methotrexate score @ 24wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
51.65 vs 52.44 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
Leeds Enthesitis Index 0.74 vs 0.95 Methotrexate score @ 12wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
0.53 vs 0.61 Methotrexate score @ 24wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
0.74 vs 0.65 Methotrexate score @ 36wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
0.5 vs 0.43 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
Leeds Dactylitis Index 2.22 vs 11.46 Methotrexate score @ 12wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
0.48 vs 5.04 Methotrexate score @ 24wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
3.36 vs 4.38 Methotrexate score @ 36wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
3.45 vs 6.58 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
mNAPSI 6.37 vs 4.78 Methotrexate score @ 12wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
3.12 vs 4.02 Methotrexate score @ 24wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
5.5 vs 4.47 Methotrexate score @ 36wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
7.72 vs 3.91 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
PASI 0.2 vs 1 Methotrexate score @ 12wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
0 vs 0.6 Methotrexate score @ 24wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
0 vs 0.7 Methotrexate score @ 36wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
0.55 vs 0.4 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
DLQI 1 vs 1 Methotrexate score @ 24wk
absolute value · score
NCT04108468 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
1 vs 1 Methotrexate score @ 52wk
NCT04108468 · Phase 3 · registry result, not featured evidence · combination

+ 19 further endpoints in the CSV export.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Rheumatoid ArthritisPEGylated anti-TNF Fab' fragment
Weak signal

NCT03357471 · Phase 3 · completed

Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.

Next expected readout: March 2028 · NCT03414502 (registry estimate)

Reported efficacy

Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Certolizumab Pegol Q2W Injection by e-Device (SS) 100 percentage of subjects (95% CI 91.3 to 100) | Certolizumab Pegol Q4W Injection by e-Device (SS) 96.88 percentage of subjects (95% CI 86 to 99.8)

Result source: NCT03357471

golimumab · Simponi

Marketed by Johnson & Johnson

Approved in Rheumatoid Arthritismonoclonal antibody (fully human IgG1)
Partial signal

NCT00264537 · Phase 3 · completed

This trial was well designed -- randomized, fully blinded, and placebo-controlled with over 600 patients -- but its two main outcomes told different stories: the joint-damage (structural) outcome clearly favored golimumab plus methotrexate, while the joint-response (ACR50) outcome for the combined golimumab groups narrowly missed statistical significance against placebo, with only one of the individual dose comparisons reaching significance on its own. A well-designed trial with a split result on its co-primary outcomes does not qualify as strong evidence of benefit.

Reported efficacy

ACR20 response at week 14; change from baseline in HAQ score at week 24: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant. (met)

Result source: NCT00264550

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcertolizumab pegolgolimumab
ACR2054.8% vs 23.9%+30.9 vs placebowk 24 · n 312NCT02151851
21 other results
  • 51.1% vs 25.9% wk 12 · n 851 · Phase 3 · primary NCT00717236
  • 77.6% vs 28.6% 400 mg · wk 12 · n 85 · Phase 2/3 · primary NCT00791999
  • 67.2% vs 14.9% 200mg · wk 12 · n 116 · Phase 3 · primary NCT00791921
  • 76.8% vs 28.6% 200 mg · wk 12 · n 82 · Phase 2/3 · primary NCT00791999
  • 62.5% vs 28.6% 100 mg · wk 12 · n 72 · Phase 2/3 · primary NCT00791999
  • 66.7% vs 27.5% 200mg · wk 24 · n 81 · Phase 3 · primary NCT00993317
  • 69% vs 61.5% wk 52 · n 655 · Phase 3 · secondary NCT01519791
  • 71.8% vs 24.7% 400 mg · wk 24 · n 85 · Phase 2/3 · secondary NCT00791999
  • 36.5% vs 15.3% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 63.8% vs 11.4% 200mg · wk 24 · n 116 · Phase 3 · secondary NCT00791921
  • 73.2% vs 24.7% 200 mg · wk 24 · n 82 · Phase 2/3 · secondary NCT00791999
  • 61.1% vs 24.7% 100 mg · wk 24 · n 72 · Phase 2/3 · secondary NCT00791999
  • 64.2% vs 37.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 86.5% vs 74.7% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 73.8% vs 74.7% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 65.2% vs 44.9% 400 mg · wk 34 · n 69 · Phase 4 · primary NCT00580840
  • 67.1% vs 44.9% 200 mg · wk 34 · n 70 · Phase 4 · primary NCT00580840
  • 61.5% vs 0% wk 12 · n 26 · Phase 4 · primary NCT01147341
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 54.5% vs 62.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
44.4% vs 33.1%+11.3 vs placebo100 mg + placebo · wk 14 · n 133NCT00264550
25 other results
  • 36.5% vs 18% 100 mg · wk 14 · n 148 · Phase 3 · primary NCT00299546
  • 40.9% vs 15.9% 50 mg · wk 14 · n 132 · Phase 3 · primary NCT01248780
  • 34.7% vs 18% 50 mg · wk 14 · n 147 · Phase 3 · primary NCT00299546
  • 58.5% vs 24.9% 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · primary NCT00973479
  • 56.2% vs 33.1% 100 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 55.1% vs 33.1% 50 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 51.6% vs 49.4% 100 mg + placebo · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 35.3% vs 27.8% 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 42.6% vs 16% 100 mg · wk 24 · n 148 · Phase 3 · secondary NCT00299546
  • 42.4% vs 15.9% 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 31.3% vs 16% 50 mg · wk 24 · n 147 · Phase 3 · secondary NCT00299546
  • 48.1% vs 27.9% 4 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 39.8% vs 27.9% 2 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 61.6% vs 49.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% wk 24 · n 318 · Phase 3 · secondary NCT00264537
  • 59.6% vs 27.8% 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 59.6% vs 27.8% 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 51.6% vs 27.9% 4 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 55% vs 27.9% 2 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 55.9% vs 37.1% 100 mg every 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 79.4% vs 37.1% 100 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 60% vs 37.1% 50 mg every 4 weeks · wk 16 · n 35 · Phase 2 · primary NCT00207714
  • 50% vs 37.1% 50 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 62% vs 65.6% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896
ACR5036.5% vs 7.1%+29.4 vs placebowk 24 · n 312NCT02151851
11 other results
  • 26.6% vs 9.9% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 61.8% vs 52.6% wk 52 · n 655 · Phase 3 · secondary NCT01519791
  • 20.8% vs 7.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 43.2% vs 20% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 25.9% vs 12.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 80.2% vs 68.4% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 71.4% vs 68.4% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 52.2% vs 30.4% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 50% vs 30.4% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • 27.3% vs 37.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 19.2% vs 0% wk 12 · n 26 · Phase 4 · secondary NCT01147341
32.7% vs 29.4%+3.3 vs placebo100 mg + placebo · wk 24 · n 159NCT00264537
19 other results
  • 19.4% vs 13.2% 4 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 12.5% vs 13.2% 2 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 36.5% vs 29.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 40.3% vs 29.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 21.1% vs 13.2% 4 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 21.7% vs 13.2% 2 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 38.4% vs 29.4% wk 24 · n 318 · Phase 3 · primary NCT00264537
  • 18.2% vs 6.7% 100 mg · wk 14 · n 148 · Phase 3 · secondary NCT00299546
  • 15% vs 6.7% 50 mg · wk 14 · n 147 · Phase 3 · secondary NCT00299546
  • 34.9% vs 13.2% 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 28.9% vs 35.8% 100 mg + placebo · wk 24 · n 90 · Phase 3 · secondary NCT00264537
  • 11.6% vs 9.3% 4 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 8.6% vs 9.3% 2 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 44.6% vs 35.8% 100 mg + methotrexate · wk 24 · n 83 · Phase 3 · secondary NCT00264537
  • 44.2% vs 35.8% 50 mg + methotrexate · wk 24 · n 86 · Phase 3 · secondary NCT00264537
  • 25% vs 9.3% 4 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 18.6% vs 9.3% 2 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 44.4% vs 35.8% wk 24 · n 169 · Phase 3 · secondary NCT00264537
  • 34.8% vs 43.4% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896
ACR7051.3% vs 39.9%+11.4 vs placebowk 52 · n 655NCT01519791
9 other results
  • 12.9% vs 2.8% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 13.6% vs 0% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 70.6% vs 60.8% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 16.7% vs 2.7% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 9.4% vs 3.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 17.3% vs 2.5% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 63.1% vs 60.8% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 37.7% vs 15.9% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 30% vs 15.9% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
16.1% vs 25.9%vs Golimumab100 mg · wk 24.14 · n 70NCT01715896
DAS28-CRP remission16% vs 5.7%+10.3 vs placebowk 12 · n 851NCT00717236—Trial running · NCT03414502
HAQ-DI, change-0.5 vs -0.2−0.3 vs placebowk 24 · n 306NCT02151851
8 other results
  • -0.4 vs -0.2 wk 12 · n 826 · Phase 3 · secondary NCT00717236
  • -1.0 vs -0.8 wk 52 · n 645 · Phase 3 · secondary NCT01519791
  • -0.3 vs -0.0 200 mg · wk 24 · n 91 · Phase 3 · secondary NCT00674362
  • -0.5 vs -0.2 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • -0.5 vs -0.8 wk 16 · n 23 · Phase 3 · secondary NCT01235598
  • -0.6 vs -0.4 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • -0.7 vs -0.4 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
0.1 vs 0.1±0 vs placebo100 mg + placebo · wk 24 · n 133NCT00264550
8 other results
  • 0.5 vs 0.1 100 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.3 vs 0.1 100 mg + placebo · wk 14 · n 133 · Phase 3 · secondary NCT00264550
  • -0.3 vs 0.2 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 0.5 vs 0.1 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · secondary NCT00973479
  • 0.4 vs 0.1 100 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • -0.4 vs -0.6 100 mg · wk 24.14 · n 70 · Phase 2 · secondary NCT01715896
Modified Sharp score, change0.4 vs 1.6−1.2 vs placebowk 52 · n 158NCT01451203
6 other results
  • 0.2 vs 1.8 wk 52 · n 528 · Phase 3 · secondary NCT01519791
  • 0.3 vs 0.9 wk 24 · n 158 · Phase 3 · secondary NCT01451203
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
1.3 vs 1.4−0.1 vs placebo100 mg + placebo · wk 52 · n 159NCT00264537
11 other results
  • 0.1 vs 1.4 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.7 vs 1.4 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.4 vs 1.4 wk 52 · n 318 · Phase 3 · primary NCT00264537
  • 2.2 vs 2.2 100 mg + placebo · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 0.2 vs 2.2 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 1.3 vs 2.2 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0.0 vs 1.1 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 0.7 vs 2.2 wk 52 · n 318 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 0 vs 0 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550

ACR20

certolizumab pegol
54.8% vs 23.9%+30.9 vs placebowk 24 · n 312NCT02151851
21 other results
  • 51.1% vs 25.9% wk 12 · n 851 · Phase 3 · primary NCT00717236
  • 77.6% vs 28.6% 400 mg · wk 12 · n 85 · Phase 2/3 · primary NCT00791999
  • 67.2% vs 14.9% 200mg · wk 12 · n 116 · Phase 3 · primary NCT00791921
  • 76.8% vs 28.6% 200 mg · wk 12 · n 82 · Phase 2/3 · primary NCT00791999
  • 62.5% vs 28.6% 100 mg · wk 12 · n 72 · Phase 2/3 · primary NCT00791999
  • 66.7% vs 27.5% 200mg · wk 24 · n 81 · Phase 3 · primary NCT00993317
  • 69% vs 61.5% wk 52 · n 655 · Phase 3 · secondary NCT01519791
  • 71.8% vs 24.7% 400 mg · wk 24 · n 85 · Phase 2/3 · secondary NCT00791999
  • 36.5% vs 15.3% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 63.8% vs 11.4% 200mg · wk 24 · n 116 · Phase 3 · secondary NCT00791921
  • 73.2% vs 24.7% 200 mg · wk 24 · n 82 · Phase 2/3 · secondary NCT00791999
  • 61.1% vs 24.7% 100 mg · wk 24 · n 72 · Phase 2/3 · secondary NCT00791999
  • 64.2% vs 37.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 86.5% vs 74.7% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 73.8% vs 74.7% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 65.2% vs 44.9% 400 mg · wk 34 · n 69 · Phase 4 · primary NCT00580840
  • 67.1% vs 44.9% 200 mg · wk 34 · n 70 · Phase 4 · primary NCT00580840
  • 61.5% vs 0% wk 12 · n 26 · Phase 4 · primary NCT01147341
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 54.5% vs 62.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
golimumab
44.4% vs 33.1%+11.3 vs placebo100 mg + placebo · wk 14 · n 133NCT00264550
25 other results
  • 36.5% vs 18% 100 mg · wk 14 · n 148 · Phase 3 · primary NCT00299546
  • 40.9% vs 15.9% 50 mg · wk 14 · n 132 · Phase 3 · primary NCT01248780
  • 34.7% vs 18% 50 mg · wk 14 · n 147 · Phase 3 · primary NCT00299546
  • 58.5% vs 24.9% 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · primary NCT00973479
  • 56.2% vs 33.1% 100 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 55.1% vs 33.1% 50 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 51.6% vs 49.4% 100 mg + placebo · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 35.3% vs 27.8% 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 42.6% vs 16% 100 mg · wk 24 · n 148 · Phase 3 · secondary NCT00299546
  • 42.4% vs 15.9% 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 31.3% vs 16% 50 mg · wk 24 · n 147 · Phase 3 · secondary NCT00299546
  • 48.1% vs 27.9% 4 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 39.8% vs 27.9% 2 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 61.6% vs 49.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% wk 24 · n 318 · Phase 3 · secondary NCT00264537
  • 59.6% vs 27.8% 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 59.6% vs 27.8% 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 51.6% vs 27.9% 4 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 55% vs 27.9% 2 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 55.9% vs 37.1% 100 mg every 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 79.4% vs 37.1% 100 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 60% vs 37.1% 50 mg every 4 weeks · wk 16 · n 35 · Phase 2 · primary NCT00207714
  • 50% vs 37.1% 50 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 62% vs 65.6% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896

ACR50

certolizumab pegol
36.5% vs 7.1%+29.4 vs placebowk 24 · n 312NCT02151851
11 other results
  • 26.6% vs 9.9% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 61.8% vs 52.6% wk 52 · n 655 · Phase 3 · secondary NCT01519791
  • 20.8% vs 7.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 43.2% vs 20% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 25.9% vs 12.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 80.2% vs 68.4% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 71.4% vs 68.4% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 52.2% vs 30.4% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 50% vs 30.4% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • 27.3% vs 37.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 19.2% vs 0% wk 12 · n 26 · Phase 4 · secondary NCT01147341
golimumab
32.7% vs 29.4%+3.3 vs placebo100 mg + placebo · wk 24 · n 159NCT00264537
19 other results
  • 19.4% vs 13.2% 4 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 12.5% vs 13.2% 2 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 36.5% vs 29.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 40.3% vs 29.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 21.1% vs 13.2% 4 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 21.7% vs 13.2% 2 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 38.4% vs 29.4% wk 24 · n 318 · Phase 3 · primary NCT00264537
  • 18.2% vs 6.7% 100 mg · wk 14 · n 148 · Phase 3 · secondary NCT00299546
  • 15% vs 6.7% 50 mg · wk 14 · n 147 · Phase 3 · secondary NCT00299546
  • 34.9% vs 13.2% 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 28.9% vs 35.8% 100 mg + placebo · wk 24 · n 90 · Phase 3 · secondary NCT00264537
  • 11.6% vs 9.3% 4 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 8.6% vs 9.3% 2 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 44.6% vs 35.8% 100 mg + methotrexate · wk 24 · n 83 · Phase 3 · secondary NCT00264537
  • 44.2% vs 35.8% 50 mg + methotrexate · wk 24 · n 86 · Phase 3 · secondary NCT00264537
  • 25% vs 9.3% 4 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 18.6% vs 9.3% 2 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 44.4% vs 35.8% wk 24 · n 169 · Phase 3 · secondary NCT00264537
  • 34.8% vs 43.4% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896

ACR70

certolizumab pegol
51.3% vs 39.9%+11.4 vs placebowk 52 · n 655NCT01519791
9 other results
  • 12.9% vs 2.8% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 13.6% vs 0% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 70.6% vs 60.8% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 16.7% vs 2.7% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 9.4% vs 3.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 17.3% vs 2.5% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 63.1% vs 60.8% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 37.7% vs 15.9% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 30% vs 15.9% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
golimumab
16.1% vs 25.9%vs Golimumab100 mg · wk 24.14 · n 70NCT01715896

DAS28-CRP remission

certolizumab pegol
16% vs 5.7%+10.3 vs placebowk 12 · n 851NCT00717236
golimumab
—Trial running · NCT03414502

HAQ-DI, change

certolizumab pegol
-0.5 vs -0.2−0.3 vs placebowk 24 · n 306NCT02151851
8 other results
  • -0.4 vs -0.2 wk 12 · n 826 · Phase 3 · secondary NCT00717236
  • -1.0 vs -0.8 wk 52 · n 645 · Phase 3 · secondary NCT01519791
  • -0.3 vs -0.0 200 mg · wk 24 · n 91 · Phase 3 · secondary NCT00674362
  • -0.5 vs -0.2 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • -0.5 vs -0.8 wk 16 · n 23 · Phase 3 · secondary NCT01235598
  • -0.6 vs -0.4 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • -0.7 vs -0.4 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
golimumab
0.1 vs 0.1±0 vs placebo100 mg + placebo · wk 24 · n 133NCT00264550
8 other results
  • 0.5 vs 0.1 100 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.3 vs 0.1 100 mg + placebo · wk 14 · n 133 · Phase 3 · secondary NCT00264550
  • -0.3 vs 0.2 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 0.5 vs 0.1 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · secondary NCT00973479
  • 0.4 vs 0.1 100 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • -0.4 vs -0.6 100 mg · wk 24.14 · n 70 · Phase 2 · secondary NCT01715896

Modified Sharp score, change

certolizumab pegol
0.4 vs 1.6−1.2 vs placebowk 52 · n 158NCT01451203
6 other results
  • 0.2 vs 1.8 wk 52 · n 528 · Phase 3 · secondary NCT01519791
  • 0.3 vs 0.9 wk 24 · n 158 · Phase 3 · secondary NCT01451203
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
golimumab
1.3 vs 1.4−0.1 vs placebo100 mg + placebo · wk 52 · n 159NCT00264537
11 other results
  • 0.1 vs 1.4 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.7 vs 1.4 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.4 vs 1.4 wk 52 · n 318 · Phase 3 · primary NCT00264537
  • 2.2 vs 2.2 100 mg + placebo · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 0.2 vs 2.2 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 1.3 vs 2.2 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0.0 vs 1.1 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 0.7 vs 2.2 wk 52 · n 318 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 0 vs 0 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. certolizumab pegol: 14 of 14 rows · golimumab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccertolizumab pegol
Rows use multiple source trials
golimumab
Rows use multiple source trials
ACR20
responder rate · % of participants
No placebo or comparator arm
81.3% (n=841)a,b,c
NCT00175877 · Phase 3
8 other source trials
83.3% (n=12) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
76.7% (n=43) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
90.7% (n=43) @ 52wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
70% (n=110) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
81.7% (n=493) @ 52wk
NCT00160641 · Phase 3 · registry result, not featured evidence
74.2% (n=565)
NCT00160641 · Phase 3 · registry result, not featured evidence
58.1% (n=370) @ 52wk
NCT00160693 · Phase 3 · registry result, not featured evidence
57.2% (n=402)
NCT00160693 · Phase 3 · registry result, not featured evidence
13.2% (n=91) @ 52wk50 mg SCd,a,b,c
NCT01004432 · Phase 3 · combination
show 1 more dose
9.2% (n=184) @ 52wk2 mg/kg IV
NCT01004432 · Phase 3 · combination
Boolean Remission
responder rate · % of participants
50% (n=84) vs 35.4% (n=79) placebo @ 104wkQ2Wd,e,a,b,f
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
52.4% (n=126) vs 35.4% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
1.4% (n=70) vs 8.9% (n=68) Golimumab @ 24.14wk100 mge,a,b,f
NCT01715896 · Phase 2 · registry result, not featured evidence
CDAI Clinical Remission
responder rate · % of participants
52.4% (n=84) vs 43% (n=79) placebo @ 104wkQ2Wd,e,a,b,f
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
55.6% (n=126) vs 43% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
5.7% (n=70) vs 17.6% (n=68) Golimumab @ 24.14wk100 mge,a,b,f
NCT01715896 · Phase 2 · registry result, not featured evidence
DAS28-CRP
absolute change · score
-2.27 vs -2.5 placebo score @ 16wke,a,b,g
NCT01235598 · Phase 3 · registry result, not featured evidence
-2.11 vs -2.4 Golimumab score @ 24.14wk100 mge,a,b,g
NCT01715896 · Phase 2 · registry result, not featured evidence
DAS28-ESR
absolute change · score
No placebo or comparator arm
-3.222 scorea,b,c
NCT00175877 · Phase 3
3 other source trials
-2.14 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-2.26 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-2.99 score
NCT00160641 · Phase 3 · registry result, not featured evidence
0.209 score @ 76wk50 mg SCd,a,b,c
NCT01004432 · Phase 3 · combination
show 3 more doses
-0.136 score @ 76wk50 mg SC
NCT01004432 · Phase 3 · combination
-0.013 score @ 76wk50 mg SC
NCT01004432 · Phase 3 · combination
-0.017 score @ 76wk2 mg/kg IV
NCT01004432 · Phase 3 · combination
DAS28-ESR Remission
responder rate · % of participants
52.4% (n=84) vs 44.3% (n=79) placebo @ 104wkQ2Wd,e,a,b,f
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
63.5% (n=126) vs 44.3% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
17.3% (n=70) vs 19% (n=68) Golimumab @ 24.14wk100 mge,a,b,f
NCT01715896 · Phase 2 · registry result, not featured evidence
EULAR Good
responder rate · % of participants
Good Response
71.4% (n=21) vs 66.7% (n=12) placebo @ 16wke,a,b,g
Good Response
NCT01235598 · Phase 3 · registry result, not featured evidence
27.1% (n=70) vs 41.2% (n=68) Golimumab @ 24.14wk*100 mge,a,b,g
Good response
NCT01715896 · Phase 2 · registry result, not featured evidence · converted to % from 19 participants as posted
EULAR Good, Moderate
responder rate · % of participants
94% (n=84) vs 88.6% (n=79) placebo @ 104wkQ2Wd,a,h
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
98.4% (n=126) vs 88.6% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
81.3% (n=395) vs 40.1% (n=197) placebo @ 14wk2 mg/kg + MTXa,h
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
4 other source trials
69% (n=129) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 89 Participants as posted
62.5% (n=128) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
73.4% (n=128) vs 44.2% (n=129) placebo @ 14wk*4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 94 Participants as posted
64.3% (n=129) vs 44.2% (n=129) placebo @ 14wk*4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
EULAR Moderate
responder rate · % of participants
Moderate Response
23.8% (n=21) vs 25% (n=12) placebo @ 16wke,a,b,g
Moderate Response
NCT01235598 · Phase 3 · registry result, not featured evidence
50% (n=70) vs 41.2% (n=68) Golimumab @ 24.14wk*100 mge,a,b,g
Moderate response
NCT01715896 · Phase 2 · registry result, not featured evidence · converted to % from 35 participants as posted
SDAI Remission
responder rate · % of participants
53.6% (n=84) vs 41.8% (n=79) placebo @ 104wkQ2Wd,e,a,b,f
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
57.1% (n=126) vs 41.8% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
7.2% (n=70) vs 18.9% (n=68) Golimumab @ 24.14wk100 mge,a,b,f
NCT01715896 · Phase 2 · registry result, not featured evidence
Dropout rate
—Q2Wi
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
show 40 more results
—Q4W
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
41.3%
NCT00175877 · Phase 3
66.7%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
31.1%
NCT01443364 · Phase 4 · registry result, not featured evidence
47.7%CDAI to Assess Response to Cimzia
NCT01255761 · Phase 4 · registry result, not featured evidence
49.3%RAPID3 to Assess Response to Cimzi
NCT01255761 · Phase 4 · registry result, not featured evidence
3.7%
NCT01147341 · Phase 4 · registry result, not featured evidence
—400 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
—200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
2.7%Cimzia
NCT00993668 · Phase 4 · registry result, not featured evidence
—Cimzia (Single Blind)
NCT00993668 · Phase 4 · registry result, not featured evidence
2.4%Open-label Cimzia (Cimzia in Feede
NCT02319642 · Phase 3 · registry result, not featured evidence
4.2%Open-label Cimzia (Placebo in Feed
NCT02319642 · Phase 3 · registry result, not featured evidence
—
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
55.8%
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
15.7%Q2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
11.8%Q4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
31.1%
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
30.2%400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
25%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
32.6%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
41.8%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
14.3%
NCT01235598 · Phase 3 · registry result, not featured evidence
26.7%
NCT00843778 · Phase 3 · registry result, not featured evidence
8.3%
NCT01374971 · Phase 3 · registry result, not featured evidence
39%
NCT00160641 · Phase 3 · registry result, not featured evidence
29.4%200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
8.3%
NCT00753454 · Phase 3 · registry result, not featured evidence
9.4%
NCT00717236 · Phase 3 · registry result, not featured evidence
58.5%
NCT00160693 · Phase 3 · registry result, not featured evidence
12.5%200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
29.3%200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
23.5%400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
19.5%200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
29.2%100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
30.3%
NCT04740814 · Phase 1 · registry result, not featured evidence
36.5%100 mg + placeboj
NCT00264537 · Phase 3
show 35 more results
—100 mg SC
NCT00264537 · Phase 3
—50 mg SC
NCT00264537 · Phase 3
37.7%100 mg + methotrexate
NCT00264537 · Phase 3 · combination
31.4%50 mg + methotrexate
NCT00264537 · Phase 3 · combination
30.8%100 mg + placebo
NCT00264550 · Phase 3
—100 mg SC injections
NCT00264550 · Phase 3
—50 mg SC injections
NCT00264550 · Phase 3
33.7%100 mg + MTX
NCT00264550 · Phase 3 · combination
19.1%50 mg + MTX
NCT00264550 · Phase 3 · combination
—50mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—2mg/kg IV
NCT01004432 · Phase 3 · combination
—2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
17.5%2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
11.4%50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
—100 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
56.2%100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
—50 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
60.1%50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
8.3%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—2 mg/kg intravenous + 50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
15.7%100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
23.5%100 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
14.7%100 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
20%50 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
29.4%50 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—Q2Wi
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
show 40 more results
—Q4W
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
16.1%
NCT00175877 · Phase 3
—
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
—
NCT01443364 · Phase 4 · registry result, not featured evidence
11.7%CDAI to Assess Response to Cimzia
NCT01255761 · Phase 4 · registry result, not featured evidence
7.9%RAPID3 to Assess Response to Cimzi
NCT01255761 · Phase 4 · registry result, not featured evidence
—
NCT01147341 · Phase 4 · registry result, not featured evidence
—400 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
—200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
0.9%Cimzia
NCT00993668 · Phase 4 · registry result, not featured evidence
—Cimzia (Single Blind)
NCT00993668 · Phase 4 · registry result, not featured evidence
1.6%Open-label Cimzia (Cimzia in Feede
NCT02319642 · Phase 3 · registry result, not featured evidence
2.1%Open-label Cimzia (Placebo in Feed
NCT02319642 · Phase 3 · registry result, not featured evidence
—
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
—
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
—Q4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
5.6%
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
14%400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
16.7%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
14%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
13.6%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
10.7%
NCT01235598 · Phase 3 · registry result, not featured evidence
11.5%
NCT00843778 · Phase 3 · registry result, not featured evidence
—
NCT01374971 · Phase 3 · registry result, not featured evidence
18%
NCT00160641 · Phase 3 · registry result, not featured evidence
4.7%200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
2.4%
NCT00753454 · Phase 3 · registry result, not featured evidence
3.9%
NCT00717236 · Phase 3 · registry result, not featured evidence
24.1%
NCT00160693 · Phase 3 · registry result, not featured evidence
6.3%200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
6.9%200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
8.2%400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
3.7%200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
4.2%100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
9.1%
NCT04740814 · Phase 1 · registry result, not featured evidence
20.1%100 mg + placeboj
NCT00264537 · Phase 3
show 35 more results
—100 mg SC
NCT00264537 · Phase 3
—50 mg SC
NCT00264537 · Phase 3
21.4%100 mg + methotrexate
NCT00264537 · Phase 3 · combination
15.1%50 mg + methotrexate
NCT00264537 · Phase 3 · combination
13.5%100 mg + placebo
NCT00264550 · Phase 3
—100 mg SC injections
NCT00264550 · Phase 3
—50 mg SC injections
NCT00264550 · Phase 3
15.7%100 mg + MTX
NCT00264550 · Phase 3 · combination
10.1%50 mg + MTX
NCT00264550 · Phase 3 · combination
—50mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—2mg/kg IV
NCT01004432 · Phase 3 · combination
—2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
8.1%2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
5.3%50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
—100 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
17.6%100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
—50 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
14.4%50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
4.5%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—2 mg/kg intravenous + 50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
8.8%100 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
2.9%100 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
5.7%50 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
11.8%50 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
Serious AEs
0%Q2Wi
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
show 40 more results
0%Q4W
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
41.6%
NCT00175877 · Phase 3
0%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
13%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
12.1%
NCT01443364 · Phase 4 · registry result, not featured evidence
10.6%CDAI to Assess Response to Cimzia
NCT01255761 · Phase 4 · registry result, not featured evidence
8.7%RAPID3 to Assess Response to Cimzi
NCT01255761 · Phase 4 · registry result, not featured evidence
2.9%
NCT01147341 · Phase 4 · registry result, not featured evidence
2.9%400 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
7.1%200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
—Cimzia
NCT00993668 · Phase 4 · registry result, not featured evidence
1.8%Cimzia (Single Blind)
NCT00993668 · Phase 4 · registry result, not featured evidence
2%Open-label Cimzia (Cimzia in Feede
NCT02319642 · Phase 3 · registry result, not featured evidence
6.3%Open-label Cimzia (Placebo in Feed
NCT02319642 · Phase 3 · registry result, not featured evidence
6.3%
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
10.6%
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
4.8%Q2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
7.1%Q4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
10.7%
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
37.2%400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
25%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
39.5%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
36.4%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
—
NCT01235598 · Phase 3 · registry result, not featured evidence
19.2%
NCT00843778 · Phase 3 · registry result, not featured evidence
0%
NCT01374971 · Phase 3 · registry result, not featured evidence
35.3%
NCT00160641 · Phase 3 · registry result, not featured evidence
9.4%200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00753454 · Phase 3 · registry result, not featured evidence
6.1%
NCT00717236 · Phase 3 · registry result, not featured evidence
45.8%
NCT00160693 · Phase 3 · registry result, not featured evidence
5.2%200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
11.2%200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
5.9%400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
4.9%200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
4.2%100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
6.1%
NCT04740814 · Phase 1 · registry result, not featured evidence
—100 mg + placeboj
NCT00264537 · Phase 3
show 35 more results
38.7%100 mg SC
NCT00264537 · Phase 3
32%50 mg SC
NCT00264537 · Phase 3
—100 mg + methotrexate
NCT00264537 · Phase 3 · combination
—50 mg + methotrexate
NCT00264537 · Phase 3 · combination
—100 mg + placebo
NCT00264550 · Phase 3
45.7%100 mg SC injections
NCT00264550 · Phase 3
31.4%50 mg SC injections
NCT00264550 · Phase 3
—100 mg + MTX
NCT00264550 · Phase 3 · combination
—50 mg + MTX
NCT00264550 · Phase 3 · combination
4.4%50mg SC
NCT01004432 · Phase 3 · combination
2.7%50 mg SC
NCT01004432 · Phase 3 · combination
4.6%50 mg SC
NCT01004432 · Phase 3 · combination
4.7%50 mg SC
NCT01004432 · Phase 3 · combination
5.4%2mg/kg IV
NCT01004432 · Phase 3 · combination
19.7%2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
—2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
6.1%50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
33.3%100 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
—100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
34.7%50 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
6%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
2.7%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
6.9%2 mg/kg intravenous + 50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
6.8%50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence
6.3%4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
13.3%2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
9.1%50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
14%4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
13.7%2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
2.9%100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
15.2%100 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
14.3%100 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
18.9%50 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
15.6%50 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
i
hypertension 18.8%
nasopharyngitis 18.7%
urinary tract infection 17.7%
NCT00175877 · Phase 3
show 34 more results
nasopharyngitis 15.3%
headache 10.7%
upper respiratory tract infection 10.3%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
influenza 11.4%
arthralgia 6.8%
bronchitis 5.3%
NCT01443364 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 10.4%
urinary tract infection 10.4%
bronchitis 6%
NCT01255761 · Phase 4 · registry result, not featured evidence
urinary tract infection 10.6%
upper respiratory tract infection 10%
sinusitis 7.6%
NCT01255761 · Phase 4 · registry result, not featured evidence
upper respiratory infections 18.5% (placebo 0%)
rash 11.8% (placebo 0%)
bronchitis 8.8% (placebo 0%)
NCT01147341 · Phase 4 · registry result, not featured evidence
400 mg
upper respiratory tract infection 11.6% (placebo 14.5%)
urinary tract infection 8.7% (placebo 10.1%)
arthralgia 7.2% (placebo 2.9%)
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
200 mg
upper respiratory tract infection 7.1% (placebo 14.5%)
urinary tract infection 7.1% (placebo 10.1%)
arthralgia 1.4% (placebo 2.9%)
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 9.1% (placebo 5.3%)
headache 7.3% (placebo 13.2%)
nausea 5.5% (placebo 5.3%)
NCT00993668 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 15.5%
anaemia 5.6%
liver function test abnormal 4.4%
NCT02319642 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 13.7%
anaemia 5.3%
liver function test abnormal 5.3%
NCT02319642 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 15.8% (placebo 13.3%)
latent tuberculosis 7.6% (placebo 6.2%)
liver function test abnormal 7% (placebo 3.5%)
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
nausea 12.6% (placebo 10.1%)
upper respiratory tract infection 10.9% (placebo 5.1%)
urinary tract infection 7.3% (placebo 7.4%)
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
Q2W
urinary tract infection 6% (placebo 2.5%)
nasopharyngitis 4.8% (placebo 6.2%)
hypercholesterolaemia 2.4% (placebo 3.7%)
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
Q4W
nasopharyngitis 10.2% (placebo 6.2%)
hypercholesterolaemia 6.3% (placebo 3.7%)
latent tuberculosis 5.5% (placebo 0%)
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 44% (placebo 34.4%)
hepatic function abnormal 32.1% (placebo 30.6%)
nausea 24.5% (placebo 19.1%)
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
400 mg
nasopharyngitis 44.2%
pharyngitis 16.3%
bronchitis 14%
NCT00850343 · Phase 3 · registry result, not featured evidence
200 mg
rheumatoid arthritis 25%
bronchitis 16.7%
constipation 16.7%
NCT00850343 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 41.9%
eczema 27.9%
upper respiratory tract infection 20.9%
NCT00850343 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 38.2%
eczema 18.2%
pharyngitis 15.5%
NCT00850343 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 9.2%
diarrhoea 6.2%
nasopharyngitis 6.2%
NCT00843778 · Phase 3 · registry result, not featured evidence
flare of rheumatoid arthritis 8.3%
headache 8.3%
injection site reaction 8.3%
NCT01374971 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 16%
hypertension 13.6%
rheumatoid arthritis 13.4%
NCT00160641 · Phase 3 · registry result, not featured evidence
200mg
upper respiratory tract infection 14.1% (placebo 11.9%)
nasopharyngitis 11.8% (placebo 9.5%)
abdominal pain upper 5.9% (placebo 4.8%)
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 13.7%
NCT00753454 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.3% (placebo 5.3%)
headache 5.4% (placebo 5.3%)
rheumatoid arthritis 4.4% (placebo 7.7%)
NCT00717236 · Phase 3 · registry result, not featured evidence
nasopharyngitis 35.1%
upper respiratory tract infection 23.1%
back pain 22.4%
NCT00160693 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 10.4% (placebo 11.2%)
upper respiratory tract infection 6.3% (placebo 4.1%)
urinary tract infection 6.3% (placebo 5.1%)
NCT00674362 · Phase 3 · registry result, not featured evidence
200mg
nasopharyngitis 17.2% (placebo 14%)
rash 8.6% (placebo 0%)
eczema 5.2% (placebo 2.6%)
NCT00791921 · Phase 3 · registry result, not featured evidence
400 mg
nasopharyngitis 15.3% (placebo 11.7%)
hepatic function abnormal 5.9% (placebo 5.2%)
bronchitis 4.7% (placebo 1.3%)
NCT00791999 · Phase 2/3 · registry result, not featured evidence
200 mg
nasopharyngitis 13.4% (placebo 11.7%)
pharyngitis 6.1% (placebo 3.9%)
rash 4.9% (placebo 1.3%)
NCT00791999 · Phase 2/3 · registry result, not featured evidence
100 mg
hepatic function abnormal 11.1% (placebo 5.2%)
nasopharyngitis 11.1% (placebo 11.7%)
pharyngitis 6.9% (placebo 3.9%)
NCT00791999 · Phase 2/3 · registry result, not featured evidence
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence
upper respiratory tract infection 9.1%
nausea 6.1%
rheumatoid arthritis 6.1%
NCT04740814 · Phase 1 · registry result, not featured evidence
100 mg SCj
upper respiratory tract infection 25.5%
nausea 22.6%
bronchitis 16.5%
NCT00264537 · Phase 3
show 26 more results
50 mg SC
upper respiratory tract infection 26.2%
alanine aminotransferase increased 18%
bronchitis 15.1%
NCT00264537 · Phase 3
100 mg SC injections
upper respiratory tract infection 34.8%
cough 19%
nasopharyngitis 19%
NCT00264550 · Phase 3
50 mg SC injections
upper respiratory tract infection 37.1%
cough 22.9%
bronchitis 17.1%
NCT00264550 · Phase 3
50mg SC
rheumatoid arthritis 9.9%
arthralgia 8.8%
bronchitis 6.6%
NCT01004432 · Phase 3 · combination
50 mg SC
upper respiratory tract infection 9.3%
depression 5.3%
sinusitis 5.3%
NCT01004432 · Phase 3 · combination
50 mg SC
upper respiratory tract infection 6.7%
headache 5.5%
urinary tract infection 5.5%
NCT01004432 · Phase 3 · combination
50 mg SC
upper respiratory tract infection 6.1%
urinary tract infection 6.1%
sinusitis 5.7%
NCT01004432 · Phase 3 · combination
2mg/kg IV
upper respiratory tract infection 8.2%
sinusitis 7.1%
bronchitis 6%
NCT01004432 · Phase 3 · combination
2 mg/kg + MTX
upper respiratory tract infection 13.7%
bronchitis 9.4%
rheumatoid arthritis 8.4%
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
50 mg
upper respiratory tract infection 19.1%
liver function test abnormal 6.1%
anaemia 1.5%
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
100 mg SC injections
upper respiratory tract infection 31.2%
nasopharyngitis 18.8%
rheumatoid arthritis 16.7%
NCT00299546 · Phase 3 · registry result, not featured evidence
50 mg SC injections
upper respiratory tract infection 25.5%
sinusitis 19.4%
headache 14.3%
NCT00299546 · Phase 3 · registry result, not featured evidence
50 mg subcutaneous
nasopharyngitis 0%
upper respiratory tract infection 0%
NCT00975130 · Phase 3 · registry result, not featured evidence
50 mg subcutaneous
nasopharyngitis 7.1%
upper respiratory tract infection 2.4%
NCT00975130 · Phase 3 · registry result, not featured evidence
2 mg/kg intravenous + 50 mg subcutaneous
upper respiratory tract infection 6.1%
nasopharyngitis 5.3%
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
50 mg
upper respiratory tract infection 8.5% (placebo 9.3%)
nasopharyngitis 7.7% (placebo 5.4%)
rheumatoid arthritis 5.1% (placebo 4.7%)
NCT00361335 · Phase 3 · registry result, not featured evidence
4 mg/kg
upper respiratory tract infection 12.6% (placebo 9.3%)
rheumatoid arthritis 9.4% (placebo 4.7%)
bronchitis 6.3% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence
2 mg/kg
rheumatoid arthritis 15.6% (placebo 4.7%)
upper respiratory tract infection 10.9% (placebo 9.3%)
bronchitis 7.8% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence
50 mg
upper respiratory tract infection 7.2% (placebo 9.3%)
rheumatoid arthritis 6.9% (placebo 4.7%)
bronchitis 5.3% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
4 mg/kg
upper respiratory tract infection 12.2% (placebo 9.3%)
nausea 10.7% (placebo 7%)
bronchitis 7.7% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
2 mg/kg
upper respiratory tract infection 12.1% (placebo 9.3%)
nausea 11% (placebo 7%)
headache 9.3% (placebo 10.1%)
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
100 mg
nasopharyngitis 5.7%
headache 4.3%
hepatic enzyme increased 4.3%
NCT01715896 · Phase 2 · registry result, not featured evidence
100 mg every 4 weeks
headache 27.3% (placebo 20.6%)
nausea 21.2% (placebo 5.9%)
upper respiratory tract infection 15.2% (placebo 20.6%)
NCT00207714 · Phase 2 · registry result, not featured evidence
100 mg every 2 or 4 weeks
injection site erythema 28.6% (placebo 11.8%)
nasopharyngitis 22.9% (placebo 8.8%)
nausea 22.9% (placebo 5.9%)
NCT00207714 · Phase 2 · registry result, not featured evidence
50 mg every 4 weeks
headache 21.6% (placebo 20.6%)
nasopharyngitis 21.6% (placebo 8.8%)
rheumatoid arthritis 21.6% (placebo 14.7%)
NCT00207714 · Phase 2 · registry result, not featured evidence
50 mg every 2 or 4 weeks
nausea 25% (placebo 5.9%)
rheumatoid arthritis 21.9% (placebo 14.7%)
headache 18.8% (placebo 20.6%)
NCT00207714 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 3 versus Phase 2.
  6. fAssessment timepoints differ: 104 weeks versus 24.14 weeks.
  7. gAssessment timepoints differ: 16 weeks versus 24.14 weeks.
  8. hAssessment timepoints differ: 104 weeks versus 14 weeks.
  9. iPopulation comparability has not been reviewed for 39 of these studies.
  10. jPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

certolizumab pegol

ACR50 74.4% (n=43) @ 24wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00850343 · Phase 3 · registry result, not featured evidence
show 20 more results
69.8% (n=43) @ 52wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
29.1% (n=110) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
41.7% (n=12) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
69.8% (n=43) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
40.9% (n=110) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
58.3% (n=12) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
62.8% (n=43) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
63% (n=733) @ 48wk
NCT00175877 · Phase 3
66% (n=668) @ 96wk
NCT00175877 · Phase 3
65.4% (n=602) @ 144wk
NCT00175877 · Phase 3
64.8% (n=537) @ 192wk
NCT00175877 · Phase 3
58.5% (n=183) @ 240wk
NCT00175877 · Phase 3
57.6% (n=841)
NCT00175877 · Phase 3
48.9% (n=493) @ 52wk
NCT00160641 · Phase 3 · registry result, not featured evidence
51.4% (n=442) @ 100wk
NCT00160641 · Phase 3 · registry result, not featured evidence
51.7% (n=410) @ 148wk
NCT00160641 · Phase 3 · registry result, not featured evidence
56.9% (n=367) @ 196wk
NCT00160641 · Phase 3 · registry result, not featured evidence
62.5% (n=72) @ 244wk
NCT00160641 · Phase 3 · registry result, not featured evidence
47.4% (n=565)
NCT00160641 · Phase 3 · registry result, not featured evidence
27.6% (n=402)
NCT00160693 · Phase 3 · registry result, not featured evidence
ACR70 48.8% (n=43) @ 24wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00850343 · Phase 3 · registry result, not featured evidence
show 20 more results
46.5% (n=43) @ 52wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
14.5% (n=110) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
16.7% (n=12) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
46.5% (n=43) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
22.7% (n=110) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
16.7% (n=12) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
58.1% (n=43) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
37.7% (n=733) @ 48wk
NCT00175877 · Phase 3
40.7% (n=668) @ 96wk
NCT00175877 · Phase 3
41.2% (n=602) @ 144wk
NCT00175877 · Phase 3
42.8% (n=537) @ 192wk
NCT00175877 · Phase 3
34.4% (n=183) @ 240wk
NCT00175877 · Phase 3
38.2% (n=841)
NCT00175877 · Phase 3
26.2% (n=493) @ 52wk
NCT00160641 · Phase 3 · registry result, not featured evidence
27.1% (n=442) @ 100wk
NCT00160641 · Phase 3 · registry result, not featured evidence
25.6% (n=410) @ 148wk
NCT00160641 · Phase 3 · registry result, not featured evidence
29.4% (n=367) @ 196wk
NCT00160641 · Phase 3 · registry result, not featured evidence
31.9% (n=72) @ 244wk
NCT00160641 · Phase 3 · registry result, not featured evidence
25.5% (n=565)
NCT00160641 · Phase 3 · registry result, not featured evidence
7.7% (n=402)
NCT00160693 · Phase 3 · registry result, not featured evidence
Modified Sharp -0.05 score @ 0wk400 mg
absolute change · score
No placebo or comparator arm
NCT00850343 · Phase 3 · registry result, not featured evidence
show 9 more results
1.85 score @ 100wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
1.48 score @ 0wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
2.18 score @ 0wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
0.77 score @ 0wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
7.89 score @ 100wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
8.73 score @ 100wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
2.07 score @ 100wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
0.95 score @ 96wk
NCT00175877 · Phase 3
0.99 score @ 104wk
NCT00160641 · Phase 3 · registry result, not featured evidence
HAQ-DI -0.674 score
absolute change · score
No placebo or comparator arm
NCT00175877 · Phase 3
show 2 more results
-0.567 score
NCT00160641 · Phase 3 · registry result, not featured evidence
-0.305 score
NCT00160693 · Phase 3 · registry result, not featured evidence
Morning Stiffness Duration -2.147 hours
absolute change · hours
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
-2.31 hours
NCT00160641 · Phase 3 · registry result, not featured evidence
EULAR Good 42.4% (n=834)
responder rate · % of participants
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
36% (n=556)
NCT00160641 · Phase 3 · registry result, not featured evidence
SF-36 PCS 8.813 score
absolute change · score
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
6.628 score
NCT00160641 · Phase 3 · registry result, not featured evidence
SF-36 MCS 4.612 score
absolute change · score
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
4.325 score
NCT00160641 · Phase 3 · registry result, not featured evidence
DAS28-ESR LDAS 35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wk
responder rate · % of participants
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
20.5% (n=454) vs 18.1% (n=454) ADA+MTX @ 6wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
30.4% (n=454) vs 29.7% (n=454) ADA+MTX @ 12wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
All-Cause Discontinuation 0% (n=353) vs 0.0028% (n=361) ADA+MTX @ 13wk
event count · % of participants
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 7 more results
0.0198% (n=353) vs 0.0332% (n=361) ADA+MTX @ 26wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.0453% (n=353) vs 0.0609% (n=361) ADA+MTX @ 39wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.0963% (n=353) vs 0.0886% (n=361) ADA+MTX @ 52wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.1643% (n=353) vs 0.1607% (n=361) ADA+MTX @ 65wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2181% (n=353) vs 0.1967% (n=361) ADA+MTX @ 78wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2408% (n=353) vs 0.2105% (n=361) ADA+MTX @ 91wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2635% (n=353) vs 0.2247% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
Sustained Clinical 69.1% (n=131) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT01443364 · Phase 4 · registry result, not featured evidence
show 5 more results
69.8% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
65.2% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
66.7% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
64.9% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
55.8% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
Clinical Response 64.7% (n=368) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT01255761 · Phase 4 · registry result, not featured evidence
show 1 more result
76.4% (n=365) @ 12wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence

+ 87 further endpoints in the CSV export.

golimumab

EULAR 63.2% (n=133) vs 50.4% (n=133) placebo @ 14wk100 mg + placebo
responder rate · % of participants
NCT00264550 · Phase 3 · converted to % from 84 Participants as posted
show 4 more results
58.8% (n=148) vs 29.3% (n=150) placebo @ 14wk*100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
55.8% (n=147) vs 29.3% (n=150) placebo @ 14wk*50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence · converted to % from 82 participants as posted
75.3% (n=89) vs 50.4% (n=133) placebo @ 14wk*100 mg + MTX
NCT00264550 · Phase 3 · combination · converted to % from 67 Participants as posted
71.9% (n=89) vs 50.4% (n=133) placebo @ 14wk*50 mg + MTX
NCT00264550 · Phase 3 · combination · converted to % from 64 Participants as posted
EULAR 22.7% (n=75) @ 52wk50 mg SC
responder rate · % of participants
No placebo or comparator arm
NCT01004432 · Phase 3 · combination
show 6 more results
64.8% (n=3280) @ 8.67wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2127 Participants as posted
76.9% (n=3280) @ 17.33wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2522 Participants as posted
82.1% (n=3280) @ 26wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2692 Participants as posted
67% (n=3280) @ 8.67wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2199 Participants as posted
77.1% (n=3280) @ 17.33wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2530 Participants as posted
81.3% (n=3280) @ 26wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2667 Participants as posted
ACR20 7.9% (n=63) @ 76wk50 mg SC
responder rate · % of participants
No placebo or comparator arm
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
show 3 more results
8.5% (n=47) @ 76wk50 mg SC
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
11.8% (n=212) @ 76wk50 mg SC
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
15.7% (n=102) @ 76wk2 mg/kg IV
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
HAQ-DI 0.25 vs 0 placebo score @ 24wk100 mg
absolute value · score
NCT00299546 · Phase 3 · registry result, not featured evidence
show 1 more result
0.125 vs 0 placebo score @ 24wk50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
EULAR Good, Moderate 82.1% (n=3280) @ 24wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2692 Participants as posted
DAS28-ESR Remission 25.8% (n=248) @ 43.3wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Start of Month 11
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 64 Participants as posted
show 1 more result
24% (n=242) @ 43.3wk*2 mg/kg intravenous + 50 mg subcutaneous
Start of Month 11
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 58 Participants as posted
DAS28-ESR Remission 27% (n=248) @ 52wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
End of Month 12
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 67 Participants as posted
show 1 more result
24.4% (n=242) @ 52wk*2 mg/kg intravenous + 50 mg subcutaneous
End of Month 12
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 59 Participants as posted
DAS28-ESR Remission 7.7% (n=3280) @ 8.7wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-ESR - Month 2
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 251 Participants as posted
DAS28-ESR Remission 16.1% (n=3280) @ 17.3wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-ESR - Month 4
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 527 Participants as posted
DAS28-ESR Remission 23.9% (n=3280) @ 26wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-ESR - Month 6
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 784 Participants as posted
DAS28 (CRP) Remission 11.6% (n=3280) @ 8.7wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-CRP - Month 2
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 380 Participants as posted
DAS28 (CRP) Remission 23.3% (n=3280) @ 17.3wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-CRP - Month 4
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 765 Participants as posted

+ 23 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: certolizumab pegol's landscape · golimumab's landscape